Denmark· DK-28103169808
Xolair
A omalizumab product containing omalizumab, registered in Denmark by Novartis Europharm Limited. The same ATC class is registered in 16 of our 19 countries.
Checked against Danish Medicines Agency (Denmark) on
Informational only — not a medical device.
Where it is registered
Omalizumab is registered in 16 of 19 countries.
Countries holding a registration under ATC R03DX05 (omalizumab), each read from that country’s own register.
- This record: Denmark, from Danish Medicines Agency (Denmark)
- 10 of them publish a price we can compare per daily dose
Omalizumab · ATC R03DX05
16 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Italyprice
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of omalizumab costs, country by country.
Normalised to the WHO defined daily dose (16 mg), the median price runs from $0.26 in Czechia to $48.02 in Switzerland — a ×186 gap.
- 2 markets with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Omalizumab · price per daily dose (16 mg)
USD · FX 28 Sept 2026
- CH Switzerland$48.02
- CZ Czechia$0.26
The record
At a glance
Danish Medicines Agency (Denmark)- Active substance
- Omalizumab
- Manufacturer
- Novartis Europharm Limited
- Country
- Denmark (DK)
- ATC code
- R03DX05
- ATC class
- Omalizumab
- Defined daily dose
- 16 mg, P
- Reimbursed
- Not published by this register
- Source register
- Danish Medicines Agency (Denmark)
- Last checked
- September 30, 2026
Packs & prices · 1
- dk_varenummer28103169808
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
8 interactions on record for omalizumab.
Graded by severity as the source publishes them — 1 moderate. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Omalizumab · interactions on record
8 records
- 1 moderate
- 7 minor
Most severe, free to view
- Omacetaxine mepesuccinateL01XX40moderate
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same class
Other records under R03DX05
Omalizumab, as other registers publish it.
- FinlandOmlycloOrifarm Oy
- FinlandOmlycloParanova Oy
- FinlandOmlycloCelltrion Healthcare Hungary Kft.
- FinlandOmlycloParanova Oy
- FinlandOmlycloCelltrion Healthcare Hungary Kft.
- FinlandOmlycloCelltrion Healthcare Hungary Kft.
- DenmarkOmlycloCelltrion Healthcare Hungary Kft
- DenmarkOmlycloCelltrion Healthcare Hungary Kft
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Danish Medicines Agency (Denmark). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/ddce4c9d-6bd5-4053-93a7-5e4f0684476a GET /v1/drugs/ddce4c9d-6bd5-4053-93a7-5e4f0684476a?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "injektionsvæske, opløsning i fyldt injektionssprøjte",
"source": "dkma",
"strength": "150 mg",
"auth_role": "MOD",
"dk_drugid": "28103169808",
"substance": "Omalizumab",
"auth_procedure": "Central",
"in_medicinpriser": true,
"registration_date_serial": "39854"
}See everything about omalizumab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.